Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89


Monoclonal gammopathy of renal significance (MGRS) histopathologic classification, diagnostic workup, and therapeutic options.

Amaador K, Peeters H, Minnema MC, Nguyen TQ, Dendooven A, Vos JMI, Croockewit AJ, van de Donk NWCJ, Jacobs JFM, Wetzels JFM, Sprangers B, Abrahams AC.

Neth J Med. 2019 Sep;77(7):243-254.


Cardiac amyloidosis: the need for early diagnosis.

Oerlemans MIFJ, Rutten KHG, Minnema MC, Raymakers RAP, Asselbergs FW, de Jonge N.

Neth Heart J. 2019 Jul 29. doi: 10.1007/s12471-019-1299-1. [Epub ahead of print] Review.


[Spinal metastases: early recognition and a multidisciplinary approach].

Baumfalk AE, Verlaan JJ, Kasperts N, Amelink GJ, Minnema MC, Snijders TJ.

Ned Tijdschr Geneeskd. 2019 Jul 12;163. pii: D3961. Dutch.


Possibilities and limitations of an in vitro 3D bone marrow model for the prediction of clinical responses in patients with relapsed multiple myeloma.

Braham MVJ, Alblas J, Dhert WJA, Öner FC, Minnema MC.

Haematologica. 2019 Apr 19. pii: haematol.2018.213355. doi: 10.3324/haematol.2018.213355. [Epub ahead of print]


A Human Hematopoietic Niche Model Supporting Hematopoietic Stem and Progenitor Cells In Vitro.

Braham MVJ, Li Yim ASP, Garcia Mateos J, Minnema MC, Dhert WJA, Öner FC, Robin C, Alblas J.

Adv Healthc Mater. 2019 May;8(10):e1801444. doi: 10.1002/adhm.201801444. Epub 2019 Apr 3.


Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.

Plesner T, Arkenau HT, Gay F, Minnema MC, Boccadoro M, Moreau P, Cavenagh J, Perrot A, Laubach JP, Krejcik J, Ahmadi T, de Boer C, Chen D, Chiu C, Schecter JM, Richardson PG.

Br J Haematol. 2019 Aug;186(3):e35-e39. doi: 10.1111/bjh.15879. Epub 2019 Mar 31. No abstract available.


Bortezomib based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial.

Minnema MC, Nasserinejad K, Hazenberg B, Hegenbart U, Vlummens P, Ypma PF, Kröger N, Wu KL, Kersten MJ, Schaafsma MR, Croockewit S, de Waal E, Zweegman S, Tick L, Broijl A, Koene H, Bos G, Sonneveld P, Schönland S.

Haematologica. 2019 Mar 28. pii: haematol.2018.213900. doi: 10.3324/haematol.2018.213900. [Epub ahead of print]


Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.

Salles G, Gopal AK, Minnema MC, Wakamiya K, Feng H, Schecter JM, Wang M.

Clin Lymphoma Myeloma Leuk. 2019 May;19(5):275-284. doi: 10.1016/j.clml.2018.12.013. Epub 2019 Jan 2.


Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.

Bromberg JEC, Issa S, Bakunina K, Minnema MC, Seute T, Durian M, Cull G, Schouten HC, Stevens WBC, Zijlstra JM, Baars JW, Nijland M, Mason KD, Beeker A, van den Bent MJ, Beijert M, Gonzales M, de Jong D, Doorduijn JK.

Lancet Oncol. 2019 Feb;20(2):216-228. doi: 10.1016/S1470-2045(18)30747-2. Epub 2019 Jan 7.


Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.

Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, Rodig SJ, Ligon AH, Roemer MGM, Reddy N, Cohen JB, Assouline S, Poon M, Sharma M, Kato K, Samakoglu S, Sumbul A, Grigg A.

J Clin Oncol. 2019 Feb 20;37(6):481-489. doi: 10.1200/JCO.18.00766. Epub 2019 Jan 8.


Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma.

Braham MV, Deshantri AK, Minnema MC, Öner FC, Schiffelers RM, Fens MH, Alblas J.

Int J Nanomedicine. 2018 Nov 29;13:8105-8118. doi: 10.2147/IJN.S184262. eCollection 2018.


Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016.

Rutten KHG, Raymakers RAP, Hazenberg BPC, Nienhuis HLA, Vellenga E, Minnema MC.

Amyloid. 2018 Dec;25(4):227-233. doi: 10.1080/13506129.2018.1536043. Epub 2018 Dec 4.


MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma.

Hiemcke-Jiwa LS, Leguit RJ, Snijders TJ, Bromberg JEC, Nierkens S, Jiwa NM, Minnema MC, Huibers MMH.

Br J Haematol. 2019 Jun;185(5):974-977. doi: 10.1111/bjh.15674. Epub 2018 Nov 8. No abstract available.


CXCR4 mutations in lymphoplasmacytic lymphoma lead to altered CXCR4 expression.

Hiemcke-Jiwa LS, Leguit RJ, Jiwa NM, Huibers MMH, Minnema MC.

Br J Haematol. 2019 Jun;185(5):966-969. doi: 10.1111/bjh.15670. Epub 2018 Nov 8. No abstract available.


Clinical management of spinal metastases-The Dutch national guideline.

Bollen L, Dijkstra SPD, Bartels RHMA, de Graeff A, Poelma DLH, Brouwer T, Algra PR, Kuijlen JMA, Minnema MC, Nijboer C, Rolf C, Sluis T, Terheggen MAMB, van der Togt-van Leeuwen ACM, van der Linden YM, Taal W.

Eur J Cancer. 2018 Nov;104:81-90. doi: 10.1016/j.ejca.2018.08.028. Epub 2018 Oct 15. Review.


Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.

van de Donk NW, van der Holt B, Minnema MC, Vellenga E, Croockewit S, Kersten MJ, von dem Borne PA, Ypma P, Schaafsma R, de Weerdt O, Klein SK, Delforge M, Levin MD, Bos GM, Jie KG, Sinnige H, Coenen JL, de Waal EG, Zweegman S, Sonneveld P, Lokhorst HM.

Lancet Haematol. 2018 Oct;5(10):e479-e492. doi: 10.1016/S2352-3026(18)30149-2.


Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.

Oostvogels R, Jak M, Raymakers R, Mous R, Minnema MC.

Br J Haematol. 2018 Oct;183(1):60-67. doi: 10.1111/bjh.15504. Epub 2018 Aug 6.


'Transformation' from amyloid light chain amyloidosis to symptomatic multiple myeloma.

Rutten KHG, Raymakers RAP, Minnema MC.

Neth J Med. 2018 Jul;76(5):249-250.


Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.

Buske C, Sadullah S, Kastritis E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hájek R, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA; European Consortium for Waldenström's Macroglobulinemia.

Lancet Haematol. 2018 Jul;5(7):e299-e309. doi: 10.1016/S2352-3026(18)30087-5. Review.


Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.

Hiemcke-Jiwa LS, Leguit RJ, Snijders TJ, Jiwa NM, Kuiper JJW, de Weger RA, Minnema MC, Huibers MMH.

Crit Rev Oncol Hematol. 2018 Jul;127:56-65. doi: 10.1016/j.critrevonc.2018.05.010. Epub 2018 May 17. Review.


Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model.

Braham MVJ, Minnema MC, Aarts T, Sebestyen Z, Straetemans T, Vyborova A, Kuball J, Öner FC, Robin C, Alblas J.

Oncoimmunology. 2018 Feb 22;7(6):e1434465. doi: 10.1080/2162402X.2018.1434465. eCollection 2018.


The Dutch national guideline on metastases and hematological malignancies localized within the spine; a multidisciplinary collaboration towards timely and proactive management.

Groenen KHJ, van der Linden YM, Brouwer T, Dijkstra SPD, de Graeff A, Algra PR, Kuijlen JMA, Minnema MC, Nijboer C, Poelma DLH, Rolf C, Sluis T, Terheggen MAMB, van der Togt-van Leeuwen ACM, Bartels RHMA, Taal W.

Cancer Treat Rev. 2018 Sep;69:29-38. doi: 10.1016/j.ctrv.2018.05.013. Epub 2018 May 29. Review.


Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review.

van Westrhenen A, Smidt LCA, Seute T, Nierkens S, Stork ACJ, Minnema MC, Snijders TJ.

Br J Haematol. 2018 Aug;182(3):384-403. doi: 10.1111/bjh.15410. Epub 2018 May 29.


Endosteal and Perivascular Subniches in a 3D Bone Marrow Model for Multiple Myeloma.

Braham MVJ, Ahlfeld T, Akkineni AR, Minnema MC, Dhert WJA, Öner FC, Robin C, Lode A, Gelinsky M, Alblas J.

Tissue Eng Part C Methods. 2018 May;24(5):300-312. doi: 10.1089/ten.TEC.2017.0467. Epub 2018 Apr 18.


The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid.

Hiemcke-Jiwa LS, Minnema MC, Radersma-van Loon JH, Jiwa NM, de Boer M, Leguit RJ, de Weger RA, Huibers MMH.

Hematol Oncol. 2018 Apr;36(2):429-435. doi: 10.1002/hon.2489. Epub 2017 Dec 6.


[Unexpected symptoms of monoclonal gammopathy].

Smit PM, Abrahams AC, Schutgens RGE, Notermans NC, Minnema MC.

Ned Tijdschr Geneeskd. 2017;161:D1741. Review. Dutch.


High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy.

Vos JM, Notermans NC, D'Sa S, Lunn MP, van der Pol WL, Kraan W, Reilly MM, Chalker J, Gupta R, Kersten MJ, Pals ST, Minnema MC.

J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):1007-1009. doi: 10.1136/jnnp-2017-316689. Epub 2017 Oct 10. No abstract available.


Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement.

Hiemcke-Jiwa LS, Leguit RJ, Radersma-van Loon JH, Westerweel PE, Rood JJM, Doorduijn JK, Huibers MMH, Minnema MC.

Leuk Lymphoma. 2018 May;59(5):1256-1259. doi: 10.1080/10428194.2017.1369074. Epub 2017 Aug 29. No abstract available.


Randomized controlled trial on the effects of a supervised high intensity exercise program in patients with a hematologic malignancy treated with autologous stem cell transplantation: Results from the EXIST study.

Persoon S, ChinAPaw MJM, Buffart LM, Liu RDK, Wijermans P, Koene HR, Minnema MC, Lugtenburg PJ, Marijt EWA, Brug J, Nollet F, Kersten MJ.

PLoS One. 2017 Jul 20;12(7):e0181313. doi: 10.1371/journal.pone.0181313. eCollection 2017.


In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review.

Oostvogels R, Uniken Venema SM, de Witte M, Raymakers R, Kuball J, Kröger N, Minnema MC.

Bone Marrow Transplant. 2017 Sep;52(9):1233-1240. doi: 10.1038/bmt.2017.141. Epub 2017 Jul 10. Review.


Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, Spencer A, Hájek R, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, Berg D, Lin J, Gupta N, Esseltine DL, Richardson PG.

Br J Haematol. 2017 Aug;178(4):571-582. doi: 10.1111/bjh.14733. Epub 2017 May 9.


Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis.

Admiraal R, Nierkens S, de Witte MA, Petersen EJ, Fleurke GJ, Verrest L, Belitser SV, Bredius RGM, Raymakers RAP, Knibbe CAJ, Minnema MC, van Kesteren C, Kuball J, Boelens JJ.

Lancet Haematol. 2017 Apr;4(4):e183-e191. doi: 10.1016/S2352-3026(17)30029-7. Epub 2017 Mar 16. Erratum in: Lancet Haematol. 2017 May;4(5):e201.


Improving early diagnosis of pulmonary infections in patients with febrile neutropenia using low-dose chest computed tomography.

Gerritsen MG, Willemink MJ, Pompe E, van der Bruggen T, van Rhenen A, Lammers JW, Wessels F, Sprengers RW, de Jong PA, Minnema MC.

PLoS One. 2017 Feb 24;12(2):e0172256. doi: 10.1371/journal.pone.0172256. eCollection 2017.


The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry.

Beijers AJ, Oerlemans S, Mols F, Eurelings M, Minnema MC, Vreugdenhil A, van de Poll-Franse LV.

Ann Hematol. 2017 Apr;96(4):653-663. doi: 10.1007/s00277-017-2927-8. Epub 2017 Jan 23.


Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients.

Oostvogels R, Kneppers E, Minnema MC, Doorn RC, Franssen LE, Aarts T, Emmelot ME, Spierings E, Slaper-Cortenbach I, Westinga K, Goulmy E, Lokhorst HM, Mutis T.

Bone Marrow Transplant. 2017 Feb;52(2):228-237. doi: 10.1038/bmt.2016.250. Epub 2016 Nov 14.


Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.

Minnema MC, Kimby E, D'Sa S, Fornecker LM, Poulain S, Snijders TJ, Kastritis E, Kremer S, Fitsiori A, Simon L, Davi F, Lunn M, Castillo JJ, Patterson CJ, Le Garff-Tavernier M, Costopoulos M, Leblond V, Kersten MJ, Dimopoulos MA, Treon SP.

Haematologica. 2017 Jan;102(1):43-51. doi: 10.3324/haematol.2016.147728. Epub 2016 Oct 6.


Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Laubach JP, Palumbo A, Lisby S, Basse L, Wang J, Sasser AK, Guckert ME, de Boer C, Khokhar NZ, Yeh H, Clemens PL, Ahmadi T, Lokhorst HM, Richardson PG.

Blood. 2016 Oct 6;128(14):1821-1828. doi: 10.1182/blood-2016-07-726729. Epub 2016 Aug 16.


Cytomegalovirus Status and the Outcome of T Cell-Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation.

Verduyn Lunel FM, Raymakers R, van Dijk A, van der Wagen L, Minnema MC, Kuball J.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1883-1887. doi: 10.1016/j.bbmt.2016.07.009. Epub 2016 Jul 25.


Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes.

Vos JM, Gustine J, Rennke HG, Hunter Z, Manning RJ, Dubeau TE, Meid K, Minnema MC, Kersten MJ, Treon SP, Castillo JJ.

Br J Haematol. 2016 Nov;175(4):623-630. doi: 10.1111/bjh.14279. Epub 2016 Jul 29.


Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia.

Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, García-Sanz R, Gertz M, Kimby E, Kyriakou C, Merlini G, Minnema MC, Morel P, Morra E, Rummel M, Wechalekar A, Patterson CJ, Treon SP, Dimopoulos MA.

Blood. 2016 Sep 8;128(10):1321-8. doi: 10.1182/blood-2016-04-711234. Epub 2016 Jul 18. Review.


Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.

Castillo JJ, Garcia-Sanz R, Hatjiharissi E, Kyle RA, Leleu X, McMaster M, Merlini G, Minnema MC, Morra E, Owen RG, Poulain S, Stone MJ, Tam C, Varettoni M, Dimopoulos MA, Treon SP, Kastritis E.

Br J Haematol. 2016 Oct;175(1):77-86. doi: 10.1111/bjh.14196. Epub 2016 Jul 5.


CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.

Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, Groen RW, van Duin M, Sonneveld P, Minnema MC, Zweegman S, Chiu C, Bloem AC, Mutis T, Lokhorst HM, Sasser AK, van de Donk NW.

Blood. 2016 Aug 18;128(7):959-70. doi: 10.1182/blood-2016-03-703439. Epub 2016 Jun 15.


Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses.

de Haart SJ, Willems SM, Mutis T, Koudijs MJ, van Blokland MT, Lokhorst HM, de Weger RA, Minnema MC.

Blood Cancer J. 2016 May 20;6:e426. doi: 10.1038/bcj.2016.35. No abstract available.


Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.

de Haart SJ, Holthof L, Noort WA, Minnema MC, Emmelot ME, Aarts-Riemens T, Doshi P, Sasser K, Yuan H, de Bruijn J, Martens AC, van de Donk NW, Lokhorst HM, Groen RW, Mutis T.

Haematologica. 2016 Aug;101(8):e339-42. doi: 10.3324/haematol.2015.139667. Epub 2016 May 5. No abstract available.


Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.

Castillo JJ, D'Sa S, Lunn MP, Minnema MC, Tedeschi A, Lansigan F, Palomba ML, Varettoni M, Garcia-Sanz R, Nayak L, Lee EQ, Rinne ML, Norden AD, Ghobrial IM, Treon SP.

Br J Haematol. 2016 Mar;172(5):709-15. doi: 10.1111/bjh.13883. Epub 2015 Dec 21.


Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.

Beijers AJ, Vreugdenhil G, Oerlemans S, Eurelings M, Minnema MC, Eeltink CM, van de Poll-Franse LV, Mols F.

Support Care Cancer. 2016 Jun;24(6):2411-20. doi: 10.1007/s00520-015-3032-y. Epub 2015 Dec 3.


Treatment of Immunocompromised, Critically Ill Patients with Influenza A H1N1 Infection with a Combination of Oseltamivir, Amantadine, and Zanamivir.

Meijer WJ, Kromdijk W, van den Broek MP, Haas PJ, Minnema MC, Boucher CA, de Lange DW, Wensing AM.

Case Rep Infect Dis. 2015;2015:504975. doi: 10.1155/2015/504975. Epub 2015 Aug 9.


Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival.

Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Bos G, Schaap N, Wittebol S, de Weerdt O, Ammerlaan R, Sonneveld P.

Haematologica. 2015 Dec;100(12):e508-10. doi: 10.3324/haematol.2015.128728. Epub 2015 Sep 4. No abstract available.


Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG.

N Engl J Med. 2015 Sep 24;373(13):1207-19. doi: 10.1056/NEJMoa1506348. Epub 2015 Aug 26.


Effective treatment of Bing-Neel Syndrome with oral fludarabine: a case series of four consecutive patients.

Vos JM, Kersten MJ, Kraan W, Groeneveld ON, Linn C, Pals ST, Minnema MC.

Br J Haematol. 2016 Feb;172(3):461-4. doi: 10.1111/bjh.13483. Epub 2015 May 5. No abstract available.


Supplemental Content

Loading ...
Support Center